GILD Gilead Sciences
- Official Name: GILEAD SCIENCES, INC.
- Headquarters: 333 LAKESIDE DR, FOSTER CITY, CA, 94404-1147 US
- CEO: Daniel P. O'Day
- Website: gilead.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Lost by 0.483 | (1.466) - (0.983) | ||
| 2025-07-21 | 2 | Lost by 16.974 | (3.897) - 13.077 | ||
| 2025-07-28 | 3 | Won by 11.208 | 5.193 - (6.015) | ||
| 2025-07-29 | 2R | Won by 6.005 | 3.122 - (2.883) | ||
| 2025-08-04 | 4 | Won by 10.866 | 3.757 - (7.109) | ||
| 2025-08-06 | 1R | Lost by 2.037 | (1.575) - 0.462 | ||
| 2025-08-07 | 1R | Lost by 2.313 | (0.037) - 2.276 | ||
| 2025-08-11 | 5 | Lost by 9.440 | 4.369 - 13.809 | ||
| 2025-08-12 | 3R | Lost by 2.600 | (0.140) - 2.460 | ||
| 2025-08-18 | 6 | Lost by 1.131 | (0.968) - 0.163 | ||
| 2025-08-25 | 7 | Lost by 12.477 | (2.231) - 10.246 | ||
| 2025-09-01 | 8 | Lost by 2.403 | (1.026) - 1.377 | ||
| 2025-09-08 | 9 | Won by 2.447 | 2.716 - 0.269 | ||
| 2025-09-15 | 10 | Lost by 1.432 | (2.705) - (1.273) | ||
| 2025-09-22 | 11 | Lost by 7.729 | (0.044) - 7.685 | ||
| 2025-09-29 | 12 | Won by 0.133 | 0.114 - (0.019) | ||
| 2025-10-06 | 13 | Won by 5.571 | 0.719 - (4.852) | ||
| 2025-10-13 | 14 | Won by 1.694 TOTW | 3.790 - 2.096 | ||
| 2025-10-20 | 15 | Won by 2.549 | 4.238 - 1.689 |
Latest News
Yahoo - 2026-09-01
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimist...
Yahoo - 2026-08-31
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of ...
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Yahoo - 2026-08-31
3 Unpopular Stocks with Open Questions
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintai...
Benzinga - 2026-08-31
FDA Approves Gilead's New Single Tablet HIV Regimen
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...
Yahoo - 2026-08-28
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Yahoo - 2026-08-28
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inad...
Benzinga - 2026-08-28
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democr...
Yahoo - 2026-08-27
Gilead (GILD) Stock Looks Undervalued After A 147% Five Year Run
Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive r...
Yahoo - 2026-08-27
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
FOSTER CITY, Calif., August 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved B...
ChartMill - 2026-08-27
What's going on in today's after hours session: S&P500 movers
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable S&P500...
CNBC - 2026-08-27
FDA approves Gilead's daily HIV pill
CNBC's Annika Kim Constantino reports on the FDA's decision to approve Gilead's daily HIV pill.
Benzinga - 2026-08-27
Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapav...
CNBC - 2026-08-27
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Show more
Yahoo - 2026-08-27
What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval?
SeekingAlpha - 2026-08-27
GSK: Still One Of My Top Healthcare Picks
Yahoo - 2026-08-26
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Yahoo - 2026-08-26
Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug
Yahoo - 2026-08-25
Eli Lilly Is Pulling Away From the Rest of Healthcare
Yahoo - 2026-08-25
3 Dividend Stocks to Hold for the Next 10 Years
Benzinga - 2026-08-25
10 Health Care Stocks Whale Activity In Today’s Session
Yahoo - 2026-08-25
3 Unprofitable Stocks with Questionable Fundamentals
Yahoo - 2026-08-24
GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict
Yahoo - 2026-08-24
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Yahoo - 2026-08-24
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition
Benzinga - 2026-08-24
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Yahoo - 2026-08-24
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Benzinga - 2026-08-24
Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Yahoo - 2026-08-23
Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?
Yahoo - 2026-08-21
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
Yahoo - 2026-08-20
Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
Yahoo - 2026-08-19
Biotech Stocks Are Booming. What This Top Fund Is Buying Now.
Yahoo - 2026-08-19
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
Yahoo - 2026-08-18
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Yahoo - 2026-08-18
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
Yahoo - 2026-08-17
Gilead yanks out a thorn in its side in major court ruling
Yahoo - 2026-08-16
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
SeekingAlpha - 2026-08-16
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Yahoo - 2026-08-14
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
Yahoo - 2026-08-14
Gilead wins appeals court ruling against overseas drug imports
Yahoo - 2026-08-14
BofA biotech scorecard: Two buys and odd one out
CNBC - 2026-08-14
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
Yahoo - 2026-08-13
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Yahoo - 2026-08-13
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Yahoo - 2026-08-13
Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run
Yahoo - 2026-08-13
Why Gilead Sciences (GILD) Is Back In The Spotlight
Yahoo - 2026-08-13
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
Yahoo - 2026-08-12
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics
Yahoo - 2026-08-12
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Benzinga - 2026-08-12
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’
Yahoo - 2026-08-11
3 Healthcare Stocks with Open Questions
Yahoo - 2026-08-11
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
Benzinga - 2026-08-11
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Yahoo - 2026-08-11
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
Benzinga - 2026-08-11
Snowflake shares are trading lower. The company announced the appointment of Jonathan Beaulier as Chief Revenue Officer and reaffirmed its FY27 guidance.
Yahoo - 2026-08-11
Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration
Yahoo - 2026-08-10
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
SeekingAlpha - 2026-08-10
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Yahoo - 2026-08-10
GILD- An Attractive Biotech Stock with Solid Base Revenue Growth
Yahoo - 2026-08-08
Key HIV stat over 70% leaves BofA siding with Gilead
Yahoo - 2026-08-07
What Insmed Stock's Premium Is Actually Buying
Yahoo - 2026-08-07
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
SeekingAlpha - 2026-08-07
Amgen: The Market Is Underestimating Its Next Growth Phase
Yahoo - 2026-08-06
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
SeekingAlpha - 2026-08-06
Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings
Benzinga - 2026-08-05
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
Yahoo - 2026-08-05
Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...
Yahoo - 2026-08-05
Kymera Therapeutics Q2 Earnings Call Highlights
Yahoo - 2026-08-05
Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat
Benzinga - 2026-08-05
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123
Yahoo - 2026-08-05
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth
Yahoo - 2026-08-05
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Benzinga - 2026-08-05
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Benzinga - 2026-08-05
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target
Yahoo - 2026-08-05
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...
ChartMill - 2026-08-04
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance
Yahoo - 2026-08-04
Gilead Sciences Q2 Earnings Call Highlights
Yahoo - 2026-08-04
Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics
SeekingAlpha - 2026-08-04
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Yahoo - 2026-08-04
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
Yahoo - 2026-08-04
AHF Crowns Gilead Corporate Welfare King
Yahoo - 2026-08-04
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
Yahoo - 2026-08-04
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story
Yahoo - 2026-08-04
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up
Yahoo - 2026-08-04
Gilead Sciences Announces Second Quarter 2026 Financial Results
Yahoo - 2026-08-04
Equities Rally Intraday Amid Upbeat Earnings, Hormuz Reopening Hopes
Yahoo - 2026-08-04
Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says
SeekingAlpha - 2026-08-04
Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
Benzinga - 2026-08-04
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est
Benzinga - 2026-08-04
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Yahoo - 2026-08-04
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?
Yahoo - 2026-08-04
Gilead Sciences, Inc. Q2 2026 Earnings Call Summary
Yahoo - 2026-08-04
Compugen Ltd. Q2 2026 Earnings Call Summary
Yahoo - 2026-08-04
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Yahoo - 2026-08-04
Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
CNBC - 2026-08-03
Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers
Yahoo - 2026-08-03
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
Benzinga - 2026-08-03
SpaceX Could Swing $204 Billion After Earnings
CNBC - 2026-08-03
AstraZeneca–Bristol Myers Squibb merger 'is not highly likely to happen,' says UBS' Michael Yee
Benzinga - 2026-08-03
"California Supreme Court Rules In Favor Of Gilead Sciences In 'Duty To Innovate' Case Involving HIV Drugs" - Reuters
Yahoo - 2026-08-03
Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up
Yahoo - 2026-08-03
Compugen Reports Second Quarter 2026 Results
Benzinga - 2026-08-03
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
Yahoo - 2026-07-31
Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?
Yahoo - 2026-07-31
2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges
Yahoo - 2026-07-30
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Yahoo - 2026-07-30
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Yahoo - 2026-07-30
Do Wall Street Analysts Like Gilead Sciences Stock?
Yahoo - 2026-07-30
Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run
SeekingAlpha - 2026-07-30
Gilead: Buy The Distortion Before Q2 Clears It Up
Yahoo - 2026-07-29
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
Yahoo - 2026-07-29
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Yahoo - 2026-07-29
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
Benzinga - 2026-07-29
Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145
Yahoo - 2026-07-28
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Yahoo - 2026-07-28
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Benzinga - 2026-07-28
4 Health Care Stocks With Whale Alerts In Today’s Session
Yahoo - 2026-07-28
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
Yahoo - 2026-07-28
Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026
Yahoo - 2026-07-28
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
Benzinga - 2026-07-27
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165
Yahoo - 2026-07-24
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
ChartMill - 2026-07-24
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
Yahoo - 2026-07-24
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
SeekingAlpha - 2026-07-24
Legend Biotech: Why I'm Ready To Go Long Again
Benzinga - 2026-07-24
Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer
Benzinga - 2026-07-24
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Yahoo - 2026-07-23
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
Yahoo - 2026-07-22
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
Yahoo - 2026-07-21
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Yahoo - 2026-07-21
3 Market-Beating Stocks with Solid Fundamentals
Yahoo - 2026-07-21
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Benzinga - 2026-07-21
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
Yahoo - 2026-07-21
Gilead Sciences' Quarterly Earnings Preview: What You Need to Know
Benzinga - 2026-07-21
Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127
Yahoo - 2026-07-21
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More
Benzinga - 2026-07-20
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Yahoo - 2026-07-17
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Yahoo - 2026-07-17
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Yahoo - 2026-07-16
Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions
Benzinga - 2026-07-16
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Yahoo - 2026-07-16
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Yahoo - 2026-07-16
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Yahoo - 2026-07-13
Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
Yahoo - 2026-07-12
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
Yahoo - 2026-07-10
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
ChartMill - 2026-07-10
What's going on in today's session: S&P500 movers
Yahoo - 2026-07-10
2 Recession-Resistant Dividend Stocks to Buy and Hold
Yahoo - 2026-07-09
Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?
Yahoo - 2026-07-09
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative
Yahoo - 2026-07-08
Morgan Stanley Keeps Buy Rating on Gilead (GILD)
Yahoo - 2026-07-08
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
Yahoo - 2026-07-08
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
SeekingAlpha - 2026-07-08
A New Look At Legend Biotech: Plenty Of Upside For Carvykti
Benzinga - 2026-07-08
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166
ChartMill - 2026-07-07
Stay informed with the top movers within the S&P500 index on Tuesday.
Yahoo - 2026-07-07
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
Yahoo - 2026-07-07
BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients
Yahoo - 2026-07-07
Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer
Benzinga - 2026-07-07
RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $120
SeekingAlpha - 2026-07-07
SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn
Benzinga - 2026-07-07
Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156
Yahoo - 2026-07-06
The Cancer Therapy Strategy VERAXA Is Betting the Company On
Benzinga - 2026-07-06
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
Yahoo - 2026-07-06
Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls
Benzinga - 2026-07-06
This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Benzinga - 2026-07-06
HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155
Yahoo - 2026-07-01
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
SeekingAlpha - 2026-06-30
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
ChartMill - 2026-06-29
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector
Yahoo - 2026-06-29
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Yahoo - 2026-06-27
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Yahoo - 2026-06-27
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Yahoo - 2026-06-26
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Benzinga - 2026-06-26
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
Yahoo - 2026-06-26
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
Yahoo - 2026-06-25
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
Benzinga - 2026-06-25
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
SeekingAlpha - 2026-06-25
Is GSK Quietly Becoming An Oncology Powerhouse
Benzinga - 2026-06-25
Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For First-Line Treatment Of Breast Cancer
Yahoo - 2026-06-24
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Yahoo - 2026-06-24
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
Benzinga - 2026-06-24
Gilead Sciences Receives FDA Approval For Its Trodelvy Antibody-Dug Conjugate To Treat Adult Patients With Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer
Yahoo - 2026-06-24
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
Yahoo - 2026-06-23
Should You Buy Or Sell AbbVie Stock At $230?
Yahoo - 2026-06-23
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Yahoo - 2026-06-23
3 S&P 500 Stocks with Exciting Potential
SeekingAlpha - 2026-06-23
Gilead Sciences: The Market Is Underestimating Its Growth Runway
Benzinga - 2026-06-23
Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy To Treat Adult Patients With Unresectable Or Metastatic Triple-Negative Breast Cancer
Yahoo - 2026-06-22
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
Yahoo - 2026-06-22
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?
CNBC - 2026-06-19
U.S. opens tariff probe targeting Germany’s drug pricing policies
SeekingAlpha - 2026-06-18
Dividend Champion, Contender, And Challenger Highlights: Week Of June 21
CNBC - 2026-06-18
How to trade the SpaceX dip
Yahoo - 2026-06-18
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Yahoo - 2026-06-18
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
SeekingAlpha - 2026-06-18
Abivax: Safety Signals Loom Ahead Of The NDA Submission
Benzinga - 2026-06-17
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Yahoo - 2026-06-17
Gilead Sciences (GILD) Donates Remdesivir to Uganda
Yahoo - 2026-06-17
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
Yahoo - 2026-06-17
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
Yahoo - 2026-06-16
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
CNBC - 2026-06-16
Stocks making the biggest moves midday: SpaceX, Lumentum, Huntsman, e.l.f. Beauty, Intel & more
Yahoo - 2026-06-15
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
Yahoo - 2026-06-15
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Yahoo - 2026-06-15
Regulatory Milestone Boosts Gilead’s Presence in Liver Disease Care
Benzinga - 2026-06-15
Gilead Sciences New Supplemental Dug Application Accepted By FDA For Yeztugo 300-Mg Tablet; Regulator Sets Feb. 2, 2027 As Prescription Drug User Fee Act Action Date
Yahoo - 2026-06-15
Gilead’s New Liver Approvals Reframe PBC Goals And Revenue Mix
Yahoo - 2026-06-13
Gilead (GILD) Supports Faster South Africa Access to Lenacapavir
CNBC - 2026-06-13